Men last five times longer with premature ejaculation spray
Results of a new trial show that a blend of Lidocaine and Prilocaine spray shows promise or premature ejaculation (PE). There are currently no prescription drugs to treat premature ejaculation – the blend of currently marketed topical numbing agents allowed men to delay ejaculation five times longer compared to placebo.
The spray for PE is rapidly absorbed into the skin and differs from others because it causes less desensitization in both partners compared to other over the counter premature ejaculation products.
The finding about the success of the premature ejaculation spray come from a second study, and was presented at the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego. Study participants from Canada, the US, and Poland were able to delay ejaculation with the spray called PSD502.
According to background study information, premature ejaculation is twice as prevalent as erectile dysfunction, affecting one-third of U.S. men ages 18 – 59. The drug works to desensitize the glans of the penis, and is a blend of two topical anesthetics that are already marketed.
Professor Stanley E. Althof, PhD, Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida says "Recently, the international sexual health community agreed that PE should be defined as ejaculation occurring within approximately one minute of penetration that causes the patient distress. Now we need to work to develop treatments, and these encouraging results with PSD502 seem to be a step in the right direction."
The scientists plan to submit data about the success of the second trial for the premature ejaculation spray to the FDA in hopes of offering men a prescription option for treatment of PE. The spray had no side effects, and was well-tolerated according to the study results. Patients in the study, and their partners reported increased sexual satisfaction. Dr. Althof says, "Premature ejaculation can have a powerful negative impact on the emotional and sexual lives of men and their partners.” If approved, PSD502 would be the first prescription option for men suffering from premature ejaculation, improving sexual health for couples. The spray could be available in about a year.